4.8 Article

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

Journal

SCIENCE TRANSLATIONAL MEDICINE
Volume 13, Issue 616, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abj5413

Keywords

-

Funding

  1. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  2. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  3. Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  4. Bill AMP
  5. Melinda Gates Foundation [OPP1170236, INV-004923]
  6. National Institutes of Health [R01AI132317, R01AI121252]
  7. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272201800013C]

Ask authors/readers for more resources

Research isolated 216 monoclonal antibodies from patients with COVID-19, with three potent antibodies neutralizing the Alpha and Beta variants of SARS-CoV-2. Bispecific antibodies designed through distinct mechanisms showed high efficacy in inhibiting virus infection, with one exhibiting over 100-fold higher potency than a monoclonal antibody cocktail and protecting against disease in hamster models.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern threatens the efficacy of existing vaccines and therapeutic antibodies and underscores the need for additional antibodybased tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells collected from patients with coronavirus disease 2019. The three most potent antibodies targeted distinct regions of the receptor binding domain (RBD), and all three neutralized the SARS-CoV-2 Alpha and Beta variants. The crystal structure of the most potent antibody, CV503, revealed that it binds to the ridge region of SARS-CoV-2 RBD, competes with the angiotensin-converting enzyme 2 receptor, and has limited contact with key variant residues K417, E484, and N501. We designed bispecific antibodies by combining nonoverlapping specificities and identified five bispecific antibodies that inhibit SARS-CoV-2 infection at concentrations of less than 1 ng/ml. Through a distinct mode of action, three bispecific antibodies cross-linked adjacent spike proteins using dual N-terminal domain-RBD specificities. One bispecific antibody was greater than 100-fold more potent than a cocktail of its parent monoclonals in vitro and prevented clinical disease in a hamster model at a dose of 2.5 mg/kg. Two bispecific antibodies in our panel comparably neutralized the Alpha, Beta, Gamma, and Delta variants and wild-type virus. Furthermore, a bispecific antibody that neutralized the Beta variant protected hamsters against SARS-CoV-2 expressing the E484K mutation. Thus, bispecific antibodies represent a promising next-generation countermeasure against SARS-CoV-2 variants of concern.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available